2022-07-27-世界卫生组织-5._Influenza_B_Yamagata_Lineage_-_Egg-derived_-_Northern_Hemisphere_2022-2023_2页_190kb

B Yamagata Lineage Egg-Derived Candidate Vaccine Viruses for 2022-2023 Northern Hemisphere Influenza Season

• WHO collaborating centers perform antigenic and genetic analyses of candidate vaccine viruses for the 2022-2023 influenza season.
• All candidate vaccine viruses except otherwise specified have passed two-way haemagglutination inhibition (HI) tests, ensuring their suitability for vaccine development.
• National or regional control authorities approve the composition and formulation of vaccines for each country.
• Key viruses include B/Phuket/3073/2013 (egg-derived), with reassortants such as BVR-1B, BX-59A, BX-59B, BX-63, BX-63A, and B/Kong/3417/2014 variants.
• Virus sources are from institutions like NIBSC (UK), CDC (USA), NYMC (USA), VIDRL (Australia), and NIID (Japan), among others for development and production.
• Reference reagents and potency testing tools are calibrated by WHO Essential Regulatory Laboratories (ERLS) and available through specific institutes.
• Institutes contacted for candidate vaccine virus orders include CCDC, CDC, FCI, NIBSC, NIID, NYMC, and VIDRL, each with designated email contacts.
• Contact details for ERLs are provided for reagent orders, with support from manufacturers.
• Last updated on 28 July 2022, referencing WHO recommendations and guidelines for vaccine viruses and regulatory standards.